Want to join the conversation?
Jeff Zekauskas of JP Morgan asks about $MON's rationale on strategic deals. CEO Hugh Grant said the Bayer deal was financially inadequate but $MON is looking at this proposal relative to other strategic alternatives. The long-term value is important and $MON has built resource models and products based on this. The focus is on shareholder value.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.